Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma.
Hus M, Grzasko N, Szostek M, Pluta A, Helbig G, Woszczyk D, Adamczyk-Cioch M, Jawniak D, Legiec W, Morawska M, Kozinska J, Waciński P, Dmoszynska A. Hus M, et al. Among authors: legiec w. Ann Hematol. 2011 Oct;90(10):1161-6. doi: 10.1007/s00277-011-1276-2. Epub 2011 Jun 23. Ann Hematol. 2011. PMID: 21698395 Free PMC article. Clinical Trial.
Thalidomide treatment of resistant or relapsed multiple myeloma patients.
Hus M, Dmoszynska A, Soroka-Wojtaszko M, Jawniak D, Legiec W, Ciepnuch H, Hellmann A, Wolska-Smolen T, Skotnicki A, Manko J; Polish Multiple Myeloma Study Group. Hus M, et al. Among authors: legiec w. Haematologica. 2001 Apr;86(4):404-8. Haematologica. 2001. PMID: 11325647 Clinical Trial.
New drugs in multiple myeloma - role of carfilzomib and pomalidomide.
Jurczyszyn A, Legieć W, Helbig G, Hus M, Kyrcz-Krzemień S, Skotnicki AB. Jurczyszyn A, et al. Among authors: legiec w. Contemp Oncol (Pozn). 2014;18(1):17-21. doi: 10.5114/wo.2014.40175. Epub 2014 Jan 25. Contemp Oncol (Pozn). 2014. PMID: 24876816 Free PMC article. Review.
Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients--Report of the Polish Myeloma Group.
Usnarska-Zubkiewicz L, Dębski J, Butrym A, Legieć W, Hus M, Dmoszyńska A, Stella-Hołowiecka B, Zaucha JM, Januszczyk J, Rymko M, Torosian T, Charliński G, Lech-Marańda E, Malenda A, Jurczyszyn A, Urbańska-Ryś H, Druzd-Sitek A, Błońska D, Urbanowicz A, Hołojda J, Pogrzeba J, Rzepecki P, Hałka J, Subocz E, Becht R, Zdziarska B, Dytfeld D, Nowicki A, Bołkun Ł, Kłoczko J, Knopińska-Posłuszny W, Zubkiewicz-Kucharska A, Kuliczkowski K. Usnarska-Zubkiewicz L, et al. Among authors: legiec w. Leuk Res. 2016 Jan;40:90-9. doi: 10.1016/j.leukres.2015.11.005. Epub 2015 Nov 15. Leuk Res. 2016. PMID: 26626207
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Schjesvold FH, Dimopoulos MA, Delimpasi S, Robak P, Coriu D, Legiec W, Pour L, Špička I, Masszi T, Doronin V, Minarik J, Salogub G, Alekseeva Y, Lazzaro A, Maisnar V, Mikala G, Rosiñol L, Liberati AM, Symeonidis A, Moody V, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Hájek R, Mateos MV, Richardson PG, Sonneveld P; OCEAN (OP-103) Investigators. Schjesvold FH, et al. Among authors: legiec w. Lancet Haematol. 2022 Feb;9(2):e98-e110. doi: 10.1016/S2352-3026(21)00381-1. Epub 2022 Jan 12. Lancet Haematol. 2022. PMID: 35032434 Clinical Trial.
22 results